Evidence map›Paper›PMID 34695164›Full record

Observational studyPLoS pathogens2021

Induction of trained immunity by influenza vaccination - impact on COVID-19.

Priya A Debisarun, Katharina L Gössling, Ozlem Bulut, Gizem Kilic, Martijn Zoodsma, Zhaoli Liu, Marina Oldenburg, Nadine Rüchel, Bowen Zhang, Cheng-Jian Xu and 14 more

Registry-linked trialOpen access · goldAbstract readObservational Study
In one paragraph

Observational study in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06341374 (Impact of Sleep Disorders on Innate Immunity in COVID-19 Patients. A Cohort Study), which is not on this map. Cited by 111 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed, 4 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06341374 unknown statusnot on this mapstarted 2023, after this paper: background citation

Impact of Sleep Disorders on Innate Immunity in COVID-19 Patients. A Cohort Study

Typeobservational_patient_registrySponsorParc Taulí Hospital UniversitariRan2023 to 2024Enrolled50ConditionsApnea, Obstructive Sleep, SARS CoV 2 InfectionArmsInfluvac Tetra
3 · Its place in the literature

Who cites it

111 citing papers in PubMed, 4 syntheses or guidelines pooled it, 174 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Monocyte-derived galectin-1Nature immunology · 2026
    Article
  7. Maternal Influenza Vaccine Reduces the Risk of Respiratory Syncytial Virus and Related Respiratory Hospitalizations in Early Infancy: An Epidemiological Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  8. Review
  9. Observational
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Immune Responses to Influenza Infection in Children.Open forum infectious diseases · 2026
    Article
  17. Review
  18. Article
  19. Review
  20. Review

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 4 institutions in 3 countries.

Priya A DebisarunDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0003-3171-3903
Katharina L GösslingDepartment for Pediatric Oncology, Hematology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine University Duesseldorf, Dusseldorf, Germany.ORCID 0000-0002-2898-131X
Ozlem BulutDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0001-7077-6216
Gizem KilicDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0002-8251-1909
Martijn ZoodsmaDepartment of Computational Biology for Individualised Infection Medicine, Centre for Individualised Infection Medicine (CiiM), a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany.ORCID 0000-0003-3636-2209
Zhaoli LiuDepartment of Computational Biology for Individualised Infection Medicine, Centre for Individualised Infection Medicine (CiiM), a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany.ORCID 0000-0002-3641-4470
Marina OldenburgDepartment for Pediatric Oncology, Hematology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine University Duesseldorf, Dusseldorf, Germany.ORCID 0000-0001-5163-1724
Nadine RüchelDepartment for Pediatric Oncology, Hematology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine University Duesseldorf, Dusseldorf, Germany.ORCID 0000-0001-9657-8787
Bowen ZhangDepartment of Computational Biology for Individualised Infection Medicine, Centre for Individualised Infection Medicine (CiiM), a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany.ORCID 0000-0002-2911-9422
Cheng-Jian XuDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0003-1586-4672
Patrick StruyckenDepartment of Occupational Health & Safety, and Environmental Service, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0003-0118-8829
Valerie A C M KoekenDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0002-5783-9013
Jorge Domínguez-AndrésDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0002-9091-1961
Simone J C F M MoorlagDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0001-8884-8417
Esther TaksDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0002-6010-3971
Philipp N OstermannInstitute of Virology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine University Duesseldorf, Dusseldorf, Germany.ORCID 0000-0002-4419-6119
Lisa MüllerInstitute of Virology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine University Duesseldorf, Dusseldorf, Germany.
Heiner SchaalInstitute of Virology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine University Duesseldorf, Dusseldorf, Germany.ORCID 0000-0002-1636-4365
Ortwin AdamsInstitute of Virology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine University Duesseldorf, Dusseldorf, Germany.
Arndt BorkhardtDepartment for Pediatric Oncology, Hematology and Clinical Immunology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine University Duesseldorf, Dusseldorf, Germany.ORCID 0000-0002-6121-4737
Jaap Ten OeverDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Reinout van CrevelDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.ORCID 0000-0002-6233-6410
Yang LiDepartment of Computational Biology for Individualised Infection Medicine, Centre for Individualised Infection Medicine (CiiM), a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), Hannover, Germany.
Mihai G NeteaDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
Radboud University Nijmegen · NLDüsseldorf University Hospital · DEMedizinische Hochschule Hannover · DEUniversity of Bonn · DE

Funding

European Research Council 833247European Research Council 948207
6 · The paper itself

Abstract

Non-specific protective effects of certain vaccines have been reported, and long-term boosting of innate immunity, termed trained immunity, has been proposed as one of the mechanisms mediating these effects. Several epidemiological studies suggested cross-protection between influenza vaccination and COVID-19. In a large academic Dutch hospital, we found that SARS-CoV-2 infection was less common among employees who had received a previous influenza vaccination: relative risk reductions of 37% and 49% were observed following influenza vaccination during the first and second COVID-19 waves, respectively. The quadrivalent inactivated influenza vaccine induced a trained immunity program that boosted innate immune responses against various viral stimuli and fine-tuned the anti-SARS-CoV-2 response, which may result in better protection against COVID-19. Influenza vaccination led to transcriptional reprogramming of monocytes and reduced systemic inflammation. These epidemiological and immunological data argue for potential benefits of influenza vaccination against COVID-19, and future randomized trials are warranted to test this possibility.

Indexed as

COVID-19Cross ProtectionCytokinesDown-RegulationHumansImidazolesImmunity, InnateIncidenceInfluenza VaccinesNetherlandsPersonnel, HospitalPoly I-CProteomicsRisk FactorsSequence Analysis, RNACytokinesImidazolesInfluenza VaccinesPoly I-Cresiquimod

Identifiers

PMID34695164
PMCPMC8568262
OpenAlexW3198920134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.